Pembrolizumab in patients with programmed death ligand 1–positive advanced ovarian cancer: Analysis of KEYNOTE-028
Andréa Varga(Institut Gustave Roussy), Sarina A. Piha‐Paul(The University of Texas MD Anderson Cancer Center), Patrick A. Ott(Dana-Farber Cancer Institute), Janice M. Mehnert(Rutgers Cancer Institute of New Jersey), Dominique Berton-Rigaud, Anne Morosky(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ping Yang, Jane Ruman(Merck & Co., Inc., Rahway, NJ, USA (United States)), Daniela Matei(Northwestern University)
Cited by 284
Abstract
Related Papers
No related papers found
Powered by citation graph analysis